April 15, 2025
What happens when public interest in or access to a promising therapy outpaces research and clinical knowledge? If the experience following the legalization of cannabis is […]
April 14, 2025
TOPLINE: Recent lithium and valproate use was associated with a 34%-46% lower risk for suicide in patients with schizophrenia or bipolar disorder (BD), investigators leading a […]
April 14, 2025
MADRID — Building on a growing body of evidence, new research has reinforced the potential of avatar-based therapy to ease auditory hallucinations — one of the […]
April 14, 2025
MADRID — Rates of cannabis-induced psychosis (CIP) and cannabis use disorder (CUD) have risen across Scandinavia alongside increasing cannabis potency, accompanied by a parallel increase in […]
April 14, 2025
MADRID — Cannabidiol (CBD) extract may offer meaningful benefits for children and adolescents with autism spectrum disorder (ASD), improving social responsiveness and reducing disruptive behavior, results […]
April 11, 2025
TOPLINE: In a 52-week trial among adults with treatment-resistant depression, quetiapine augmentation was more effective than lithium augmentation in reducing symptoms, offered greater cost-effectiveness, and showed […]
April 9, 2025
Some neurologists and a consumer watchdog are raising concerns that a direct-to-consumer telehealth platform affiliated with the drug company Eli Lilly — marketed to individuals concerned […]
April 8, 2025
Referrals to NHS Talking Therapies in England have more than doubled over the past decade. However, a high dropout rate concerns clinicians and mental health experts. […]
April 8, 2025
TOPLINE: Twice-weekly administration of low-dose lysergic acid diethylamide (LSD) over 6 weeks was safe in adults with attention-deficit/hyperactivity disorder (ADHD) but was no better than placebo […]